Ambrx Biopharma Inc. | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (4)

Latest Posts

About This Stock More About This Stock
Week In Review: China Biopharmas Book $9 Billion In Deals During JP Morgan Conference Week
Article By: ChinaBio® Today
Saturday, January 13, 2024 1:20 PM EDT
Shanghai Argo Biopharma entered 2 agreements with Novartis, out-licensing four next-gen RNAi therapeutics for $185 million upfront and a total value of $4.2 billion. Additionally, Ambrx Biopharma will be acquired by Johnson & Johnson for $2 billion.
In this article: GSK, JNJ, NVS, BAYRY, BNTX, PRAX, AMAM, HLVX Also: TAK

Latest Tweets for $AMAM

No tweets yet!